Literature DB >> 26092469

Interleukin-33 and Interferon-γ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation.

Ari B Molofsky1, Frédéric Van Gool2, Hong-Erh Liang3, Steven J Van Dyken4, Jesse C Nussbaum5, Jinwoo Lee6, Jeffrey A Bluestone7, Richard M Locksley8.   

Abstract

Group 2 innate lymphoid cells (ILC2s) and regulatory T (Treg) cells are systemically induced by helminth infection but also sustain metabolic homeostasis in adipose tissue and contribute to tissue repair during injury. Here we show that interleukin-33 (IL-33) mediates activation of ILC2s and Treg cells in resting adipose tissue, but also after helminth infection or treatment with IL-2. Unexpectedly, ILC2-intrinsic IL-33 activation was required for Treg cell accumulation in vivo and was independent of ILC2 type 2 cytokines but partially dependent on direct co-stimulatory interactions via ICOSL-ICOS. IFN-γ inhibited ILC2 activation and Treg cell accumulation by IL-33 in infected tissue, as well as adipose tissue, where repression increased with aging and high-fat diet-induced obesity. IL-33 and ILC2s are central mediators of type 2 immune responses that promote tissue and metabolic homeostasis, and IFN-γ suppresses this pathway, likely to promote inflammatory responses and divert metabolic resources necessary to protect the host.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26092469      PMCID: PMC4512852          DOI: 10.1016/j.immuni.2015.05.019

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  65 in total

1.  Inherited defects in the interferon-gamma receptor or interleukin-12 signalling pathways are not sufficient to cause allergic disease in children.

Authors:  Philip M D Wood; Claire Fieschi; Capucine Picard; Tom H M Ottenhoff; Jean-Laurent Casanova; Dinakantha S Kumararatne
Journal:  Eur J Pediatr       Date:  2005-08-23       Impact factor: 3.183

2.  Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse.

Authors:  M E Brunkow; E W Jeffery; K A Hjerrild; B Paeper; L B Clark; S A Yasayko; J E Wilkinson; D Galas; S F Ziegler; F Ramsdell
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

3.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

4.  IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes.

Authors:  I Stuart Wood; Bohan Wang; Paul Trayhurn
Journal:  Biochem Biophys Res Commun       Date:  2009-04-23       Impact factor: 3.575

5.  Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters.

Authors:  Markus Feuerer; Laura Herrero; Daniela Cipolletta; Afia Naaz; Jamie Wong; Ali Nayer; Jongsoon Lee; Allison B Goldfine; Christophe Benoist; Steven Shoelson; Diane Mathis
Journal:  Nat Med       Date:  2009-07-26       Impact factor: 53.440

6.  Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance.

Authors:  Justin I Odegaard; Roberto R Ricardo-Gonzalez; Matthew H Goforth; Christine R Morel; Vidya Subramanian; Lata Mukundan; Alex Red Eagle; Divya Vats; Frank Brombacher; Anthony W Ferrante; Ajay Chawla
Journal:  Nature       Date:  2007-05-21       Impact factor: 49.962

7.  Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system.

Authors:  David Voehringer; Tiffany A Reese; Xiaozhu Huang; Kanade Shinkai; Richard M Locksley
Journal:  J Exp Med       Date:  2006-05-15       Impact factor: 14.307

8.  Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses.

Authors:  Ye Zheng; Ashutosh Chaudhry; Arnold Kas; Paul deRoos; Jeong M Kim; Tin-Tin Chu; Lynn Corcoran; Piper Treuting; Ulf Klein; Alexander Y Rudensky
Journal:  Nature       Date:  2009-02-01       Impact factor: 49.962

9.  IL-33 reduces the development of atherosclerosis.

Authors:  Ashley M Miller; Damo Xu; Darren L Asquith; Laura Denby; Yubin Li; Naveed Sattar; Andrew H Baker; Iain B McInnes; Foo Y Liew
Journal:  J Exp Med       Date:  2008-02-11       Impact factor: 14.307

10.  Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function.

Authors:  Daniel B Stetson; Markus Mohrs; R Lee Reinhardt; Jody L Baron; Zhi-En Wang; Laurent Gapin; Mitchell Kronenberg; Richard M Locksley
Journal:  J Exp Med       Date:  2003-10-06       Impact factor: 14.307

View more
  199 in total

1.  Putting the brakes on ILC2 cells.

Authors:  Christina Stehle; Philippe Saikali; Chiara Romagnani
Journal:  Nat Immunol       Date:  2016-01       Impact factor: 25.606

2.  Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses.

Authors:  Kazuyo Moro; Hiroki Kabata; Masanobu Tanabe; Satoshi Koga; Natsuki Takeno; Miho Mochizuki; Koichi Fukunaga; Koichiro Asano; Tomoko Betsuyaku; Shigeo Koyasu
Journal:  Nat Immunol       Date:  2015-11-23       Impact factor: 25.606

3.  Poor Repair of Skeletal Muscle in Aging Mice Reflects a Defect in Local, Interleukin-33-Dependent Accumulation of Regulatory T Cells.

Authors:  Wilson Kuswanto; Dalia Burzyn; Marisella Panduro; Kathy K Wang; Young Charles Jang; Amy J Wagers; Christophe Benoist; Diane Mathis
Journal:  Immunity       Date:  2016-02-09       Impact factor: 31.745

4.  Prolonged activation of IL-5-producing ILC2 causes pulmonary arterial hypertrophy.

Authors:  Masashi Ikutani; Koichi Tsuneyama; Makoto Kawaguchi; Junya Fukuoka; Fujimi Kudo; Susumu Nakae; Makoto Arita; Yoshinori Nagai; Satoshi Takaki; Kiyoshi Takatsu
Journal:  JCI Insight       Date:  2017-04-06

5.  Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells.

Authors:  Zhongming Tan; Qianghui Liu; Runqiu Jiang; Long Lv; Siamak S Shoto; Isabelle Maillet; Valerie Quesniaux; Junwei Tang; Wenjie Zhang; Beicheng Sun; Bernhard Ryffel
Journal:  Cell Mol Immunol       Date:  2017-02-13       Impact factor: 11.530

6.  IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs.

Authors:  Chien-Chang Chen; Takao Kobayashi; Koji Iijima; Fan-Chi Hsu; Hirohito Kita
Journal:  J Allergy Clin Immunol       Date:  2017-02-11       Impact factor: 10.793

7.  The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation.

Authors:  Bertrand Routy; Caroline Letendre; David Enot; Maxime Chénard-Poirier; Vikram Mehraj; Noémie Charbonneau Séguin; Khaled Guenda; Kathia Gagnon; Paul-Louis Woerther; David Ghez; Silvy Lachance
Journal:  Oncoimmunology       Date:  2016-12-27       Impact factor: 8.110

8.  TCR Transgenic Mice Reveal Stepwise, Multi-site Acquisition of the Distinctive Fat-Treg Phenotype.

Authors:  Chaoran Li; Joanna R DiSpirito; David Zemmour; Raul German Spallanzani; Wilson Kuswanto; Christophe Benoist; Diane Mathis
Journal:  Cell       Date:  2018-06-07       Impact factor: 41.582

9.  IL-33 induces immunosuppressive neutrophils via a type 2 innate lymphoid cell/IL-13/STAT6 axis and protects the liver against injury in LCMV infection-induced viral hepatitis.

Authors:  Yuejin Liang; Panpan Yi; Denley Ming Kee Yuan; Zuliang Jie; Zakari Kwota; Lynn Soong; Yingzi Cong; Jiaren Sun
Journal:  Cell Mol Immunol       Date:  2018-02-05       Impact factor: 11.530

10.  Distinct immunocyte-promoting and adipocyte-generating stromal components coordinate adipose tissue immune and metabolic tenors.

Authors:  Raul German Spallanzani; David Zemmour; Tianli Xiao; Teshika Jayewickreme; Chaoran Li; Paul J Bryce; Christophe Benoist; Diane Mathis
Journal:  Sci Immunol       Date:  2019-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.